Ifinatamab deruxtecan

DB18212InvestigationalProtein Based Therapies

Ifinatamab deruxtecan: Overview.

Mechanism
Curator reviewed
Also known as
I-DXd · IMMUNOGLOBULIN G1, ANTI-(HUMAN B7 HOMOLOG 3 PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL MABX-9001A .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MABX-9001A .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOH · MABX-9001A CYSTEINYL-DERUXTECAN
Code names
DS-7300A · MK-2400

Resolves to

Compound
UNIIC6I0GC0GX5CAS2484870-92-8
Targets
P11387TOP1Q5ZPR3CD276

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
17Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ifinatamab deruxtecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In